Market Overview

Aytu BioScience Shares Clinical Results For Natesto Testosterone Medication

Share:

Aytu BioScience (NASDAQ: AYTU) announced the publication of clinical study results demonstrating the effectiveness of Natesto regardless of patients' baseline Hypogonadism severity.

Natesto Testosterone is a medication and naturally occurring steroid hormone used to treat male hypogonadism and certain types of breast cancer.

Aytu BioScience says the acceptance of a new manuscript submitted to the Journal of the Endocrine Society, demonstrates that Natesto achieves similar symptom improvement, regardless of the degree of patients' testosterone deficiency.

"The body of clinical evidence supporting Natesto's unique efficacy and safety profile continues to grow, and we believe these new data in conjunction with the previously published and ongoing studies stand to further differentiate Natesto from the other testosterone replacement therapies," said Josh Disbrow, CEO of Aytu BioScience, in a statement.

Aytu BioScience shares are trading up 10.2% at $2.04 in Monday's pre-market session. The stock has a 52-week high of $7.80 and a 52-week low of 68 cents.

Related Links:

Karyopharm Spikes Higher After Selinexor Leak

Varian Will Acquire Embolic Bead Asset From Boston Scientific

Posted-In: News Health Care General

 

Related Articles (AYTU)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression

Deutsche Bank To Cut 18K Jobs In 'Most Fundamental Transformation' In Decades